Cargando…
Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer
BACKGROUND: Amid continued uncertainty about the management of cancer patients during the pandemic, this study sought to obtain real-world data on the use of immune checkpoint inhibitors (ICIs) before COVID-19 diagnosis and its association with severity and survival outcomes in cancer patients who c...
Autores principales: | Tan, Ruoding, Yun, Cindy, Seetasith, Arpamas, Sheinson, Daniel, Walls, Robert, Ngwa, Innocent, Reddy, Josina C, Zhang, Qing, Secrest, Matthew H, Lambert, Peter, Sarsour, Khaled |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914490/ https://www.ncbi.nlm.nih.gov/pubmed/35274714 http://dx.doi.org/10.1093/oncolo/oyab083 |
Ejemplares similares
-
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors
por: George, Saby, et al.
Publicado: (2021) -
Real‐World Clinical and Economic Outcomes in Selected Immune‐Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Zheng, Ying, et al.
Publicado: (2021) -
1574P Mortality of 1,636 COVID-19 cancer patients (pts) and associated prognostic factors
por: Ascierto, P.A., et al.
Publicado: (2021) -
Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
por: Postmus, Douwe, et al.
Publicado: (2017) -
Costs of Cancer Care Across the Disease Continuum
por: Kaye, Deborah R., et al.
Publicado: (2018)